Impact of pharmacogenomics on clinical practice in oncology

Molecular Diagnosis and Therapy

Volumn 11, Issue 2, 2007, Pages 79-82

  Marsh, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DEOXYURIDINE PHOSPHATE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; OXALIPLATIN; THIOPURINE METHYLTRANSFERASE; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE LYMPHOCYTIC LEUKEMIA; ALLELE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CHILDHOOD CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DNA POLYMORPHISM; DRUG COST; DRUG DOSE REDUCTION; DRUG FATALITY; ENZYME ACTIVITY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; METHYLATION; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; RACE DIFFERENCE; RECTUM CANCER; REVIEW; TANDEM REPEAT;

EID: 34147111853     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256226     Document Type: Review

References (47)

1. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 Dec 20; 23 (36): 9441-2
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 Jan 12; 354 (2): 166-78
3. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001 Feb 15; 409 (6822): 928-33
4. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348 (6): 538-49
5. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004 Jan 12; 90 (1): 8-11
6. Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006 Apr 15; 15 (Spec. No. 1.): R89-93
7. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001 Feb 15; 409 (6822): 860-921
8. Wheeler DL, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2005 Jan 1; 33: D39-45
9. The International HapMap Project. Nature 2003 Dec 18; 426 (6968): 789-96
10. Altshuler D, Brooks LD, Chakravarti A, et al. A haplotype map of the human genome. Nature 2005 Oct 27; 437 (7063): 1299-320
11. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet 2005 Jun; 37S: S5-10
12. Freimuth RR, Ameyaw M-M, Pritchard SC, et al. High-throughput genotyping methods for pharmacogenomic studies. Curr Pharmacogenomics 2004; 2 (1): 21-33
13. Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004 Jul 22; 351 (4): 317-9
14. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999 May 1; 93 (9): 2817-23
15. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics 2002 Jan; 3 (1): 89-98
16. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999 Dec 1; 91 (23): 2001-8
17. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003 Mar 1; 21 (5): 807-14
18. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 Jul 7; 95 (14): 8170-4
19. Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000 Feb 15; 60 (4): 950-6
20. Hall D, Ybazeta G, Destro-Bisol G, et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999 Oct; 9 (5): 591-9
21. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000 Dec 15; 60 (24): 6921-6
22. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Huntingt) 2003 May; 17 (5 Suppl. 5): 52-5
23. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999 May; 65 (5): 576-82
24. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1): 43-7
25. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004 Apr 15; 22 (8): 1382-8
26. FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 2005; 6 (7): 671-2
27. Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes [abstract]. Proc Am Soc Clin Oncol 2005; 23: 136s
28. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004 Jun; 75 (6): 501-15
29. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004 Oct; 5 (7): 835-43
30. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007 Jan; 81 (1): 42-9
31. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995 Apr 1; 55 (7): 1407-12
32. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997 Oct; 15 (10): 3223-9
33. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005 Dec; 23 (6): 533-7
34. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995 Jun; 20 (3): 191-7
35. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5? tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003 Jun 1; 63 (11): 2898-904
36. Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000 Dec; 9 (12): 1381-5
37. Marsh S, Ameyaw MM, Githang'a J, et al. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000 Dec; 16 (6): 528
38. Luo HR, Lu XM, Yao YG, et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 2002 Feb; 40 (1-2): 41-51
39. Kawakami K, Omura K, Kanehira E, et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999 Jul-Aug; 19 (4B): 3249-52
40. Marsh S, Collie-Duguid ES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999 Jun 15; 58 (3): 310-2
41. Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001 Nov; 1 (3): 175-8; discussion 79-81
42. Horie N, Takeishi K. Functional structure of the promoter region of the human thymidylate synthase gene and nuclear factors that regulate the expression of the gene. Nucleic Acids Symp Ser 1995; (34): 77-8
43. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001 Mar 15; 19 (6): 1779-86
44. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1 (1): 65-70
45. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004 Sep 1; 10 (17): 5880-8
46. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001 Sep 14; 85 (6): 827-30
47. McLeod HL, Tan B, Malyapa R, et al. Genotype-guided neoadjuvant therapy for rectal cancer [abstract]. Proc Am Soc Clin Oncol 2005; 23: 197